Herein, we present a homologous-magnetic dual-targeted nanoplatform, named Hm@TSA/As-MOF, to enhance the therapeutic effects of PD-1 antibody (α-PD-1) against HCC. Here, PDCD1 is linked to hepatocellular carcinoma.